Physiology
Erythropoiesis and Erythropoietin
Red blood cell production in the marrow, driven by a kidney oxygen sensor
Erythropoiesis is the production of red blood cells in the bone marrow, tuned by erythropoietin (EPO) — a glycoprotein hormone the kidney releases when its oxygen sensors detect that tissue O2 has fallen. Oxygen sensing runs through the HIF pathway; when it fires, EPO signals through JAK2/STAT5 on erythroid progenitors to keep them alive and drive the lineage from a hematopoietic stem cell through the erythroblast series to a nucleus-ejecting reticulocyte and finally a biconcave, enucleated erythrocyte. The marrow builds roughly 2 million red cells every second — about 200 billion a day — each requiring iron for heme and vitamin B12 plus folate for DNA synthesis. EPO was purified by Eugene Goldwasser in 1977 and cloned in 1985; the oxygen-sensing machinery earned Semenza, Ratcliffe, and Kaelin the 2019 Nobel Prize.
- Output~2 million RBCs/second
- RBC lifespan~120 days
- EPO sourceKidney interstitial fibroblasts
- Oxygen sensorHIF-2α / PHD / VHL
- SignalEPOR → JAK2 → STAT5
- NobelHIF pathway, 2019
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why erythropoiesis matters
- It is one of the body's largest manufacturing jobs. Erythrocytes make up roughly a quarter of all cells in the human body, and each lasts only about 120 days. To hold the count steady the marrow replaces some 200 billion cells a day — about 2 million a second — so the whole red-cell mass turns over roughly every four months without your noticing.
- It couples oxygen supply to red-cell supply. The same kidney cells that sit next to the tubules and sample blood oxygen also secrete EPO. That single-organ arrangement makes the kidney the body's master oxygen gauge: bleed, climb a mountain, or develop lung disease, and renal EPO rises to match red-cell output to demand.
- Kidney disease causes anemia — and EPO reverses it. Because the diseased kidney under-produces EPO, chronic kidney disease brings a predictable normocytic anemia. Recombinant human EPO (epoetin alfa, licensed 1989) and longer-acting analogs (darbepoetin) transformed the treatment of that anemia and of chemotherapy-induced anemia, sparing millions of transfusions.
- It made HIF one of biology's most important pathways. Chasing how the EPO gene senses oxygen led Semenza, Ratcliffe, and Kaelin to the hypoxia-inducible factor system that now underpins understanding of tumor angiogenesis, ischemia, and metabolism — the 2019 Nobel Prize in Physiology or Medicine.
- It powers altitude adaptation. Ascent to thin air raises EPO within a day or two; over weeks, hematocrit rises and oxygen delivery improves. Endurance athletes exploit this with "live high, train low," and Andean, Tibetan, and Ethiopian highlanders carry distinct evolved variants of the pathway.
- It is the target of blood doping. Injecting rhEPO or blocking the prolyl hydroxylases pushes the marrow to over-produce red cells — a banned but persistent form of endurance cheating whose viscosity-driven clotting risk has been linked to athlete deaths.
Common misconceptions
- "Erythropoietin is made in the bone marrow." No — EPO is made mainly in the kidney (peritubular interstitial fibroblasts) and acts on the marrow. Separating the oxygen sensor (kidney) from the factory (marrow) is the whole point of the system; it lets one organ report oxygen status for the entire body.
- "EPO tells stem cells to become red cells." EPO mostly does not instruct fate; it prevents death. Its receptor is highest on late progenitors (CFU-E), and its dominant effect is anti-apoptotic — it lets already-committed erythroid progenitors survive and finish maturing. Turn EPO off and those cells die by apoptosis; turn it up and more of them live.
- "Red cells never had a nucleus." They did. Every red cell descends from a nucleated erythroblast that condenses and physically extrudes its nucleus late in maturation; a marrow macrophage then eats the discarded nucleus. Enucleation is a mammalian specialty — birds, fish, reptiles, and amphibians keep nucleated red cells throughout life.
- "The kidney measures blood oxygen with a special receptor." There is no dedicated O2 receptor protein. Oxygen is sensed enzymatically: prolyl hydroxylases use molecular O2 as a substrate to tag HIF-α for destruction. When oxygen is scarce, the reaction simply cannot run, HIF-α accumulates, and EPO transcription switches on. The "sensor" is a chemical reaction that stalls.
- "Iron deficiency and B12 deficiency cause the same anemia." They cause opposite cell sizes. Iron shortage starves hemoglobin, so cells come out small and pale (microcytic, hypochromic). B12 or folate shortage stalls DNA synthesis while the cytoplasm keeps growing, so cells come out large (macrocytic, megaloblastic). Cell size on a blood smear is a first clue to which nutrient is missing.
- "More red cells are always better." Only up to a point. Beyond roughly a hematocrit of 50–55 percent, blood viscosity rises steeply, flow slows, and clot and stroke risk climbs. That is exactly why EPO doping and chronic mountain sickness (Monge's disease) are dangerous rather than simply performance-enhancing.
How erythropoiesis works, step by step
The trigger is oxygen. In the renal cortex, peritubular interstitial fibroblasts continuously run the HIF oxygen-sensing pathway. When arterial oxygen is normal, prolyl hydroxylase enzymes (PHD1, PHD2, PHD3) use O2 and 2-oxoglutarate to hydroxylate two proline residues on the transcription factor HIF-2α. The von Hippel-Lindau (VHL) E3 ubiquitin ligase then recognizes the hydroxylated HIF-2α, ubiquitinates it, and sends it to the proteasome — so at rest HIF-2α is destroyed almost as fast as it is made and little EPO is transcribed. When tissue oxygen falls, the hydroxylases lack their O2 substrate and stall; HIF-2α escapes degradation, dimerizes with HIF-1β (ARNT), binds the hypoxia-response element, and switches on the EPO gene. EPO protein pours into the blood.
EPO travels to the marrow and binds the erythropoietin receptor (EPOR), a cytokine receptor pre-associated with the kinase JAK2. Ligand binding brings two JAK2 molecules together; they trans-phosphorylate, then phosphorylate STAT5, which dimerizes, enters the nucleus, and drives survival genes such as BCL-xL. The net effect is anti-apoptotic: EPOR is expressed most strongly on the colony-forming unit-erythroid (CFU-E) stage, and without EPO those cells die. With EPO they survive and proceed down the lineage. Upstream sit the multipotent hematopoietic stem cell and the earlier burst-forming unit-erythroid (BFU-E); downstream lie the maturing erythroblasts.
Maturation is a fixed morphological series. The proerythroblast gives rise to the basophilic erythroblast (ribosome-rich, deep blue cytoplasm), then the polychromatic erythroblast (hemoglobin now accumulating, so cytoplasm turns gray-pink), then the orthochromatic erythroblast (cytoplasm nearly red, nucleus condensed and pushed to the edge). Across these steps the cell shrinks, chromatin condenses, and hemoglobin fills the cytoplasm. The orthochromatic erythroblast then performs the defining act of mammalian red-cell biology — enucleation: it extrudes its condensed nucleus in a thin envelope of membrane, and a resident marrow macrophage (the center of an "erythroblastic island") engulfs the ejected nucleus.
The enucleated cell is a reticulocyte. It still carries ribosomes and residual RNA and keeps synthesizing hemoglobin for a day or two — first in the marrow, then released into the blood, where it finishes maturing over about 24 hours into a fully mature erythrocyte. The mature cell is a biconcave disc about 7–8 µm across, roughly one-third hemoglobin by weight (about 270 million hemoglobin molecules), with no nucleus, no mitochondria, and no ribosomes — a specialized bag of hemoglobin that deforms to slip through capillaries and lives about 120 days before macrophages in the spleen and liver retire it and recycle its iron. Throughout, the raw materials must be present: iron for every heme, and vitamin B12 plus folate for the DNA replication that the dividing precursors require.
The erythroid lineage at a glance
| Stage | Nucleus | Key event | Hemoglobin |
|---|---|---|---|
| Hematopoietic stem cell (HSC) | Present | Multipotent; self-renews | None |
| BFU-E | Present | Earliest committed erythroid; low EPOR | None |
| CFU-E | Present | Peak EPOR; EPO-dependent survival | Trace |
| Proerythroblast | Present, large | First recognizable erythroblast | Starting |
| Basophilic erythroblast | Present | Ribosome-rich, blue cytoplasm | Low |
| Polychromatic erythroblast | Present, condensing | Gray-pink cytoplasm | Rising |
| Orthochromatic erythroblast | Condensed, extruded | Enucleation; macrophage eats nucleus | Nearly full |
| Reticulocyte | Absent | Residual RNA; finishes Hb; enters blood | High |
| Erythrocyte | Absent | Biconcave disc; ~120-day lifespan | ~33% by weight |
Iron vs vitamin B12 vs folate
| Property | Iron | Vitamin B12 (cobalamin) | Folate |
|---|---|---|---|
| Role in RBC | Core of every heme; binds O2 | DNA synthesis (with folate) | DNA synthesis (thymidine) |
| Deficiency anemia | Microcytic, hypochromic | Macrocytic, megaloblastic | Macrocytic, megaloblastic |
| Cell size effect | Small, pale cells | Large, immature cells | Large, immature cells |
| Body handling | ~3–4 g total; ~70% in Hb; recycled by macrophages | Stored in liver (years); needs intrinsic factor | Small store (weeks); dietary greens |
| Marrow demand | ~20–25 mg/day, mostly recycled | Cofactor, tiny mass | Cofactor, tiny mass |
| Classic cause of lack | Bleeding, poor absorption | Pernicious anemia (no intrinsic factor) | Poor diet, pregnancy, some drugs |
History and famous experiments
- Carnot and Deflandre (1906). The French physiologists Paul Carnot and Catherine Deflandre injected serum from anemic rabbits into normal rabbits and saw the recipients' red-cell counts rise. They proposed a circulating humoral factor they named "hémopoïétine" — the first prediction of erythropoietin, decades before it was isolated.
- Reissmann and Erslev (early 1950s). Parabiosis and plasma-transfer experiments nailed down that hypoxia in one animal stimulated red-cell production in a joined partner, confirming a blood-borne hormone. Allan Erslev's 1953 plasma-transfer study is often cited as the definitive demonstration that erythropoietin exists and is inducible by anemia.
- Jacobson and colleagues (1957). Leon Jacobson's group showed that removing the kidneys abolished the erythropoietic response to bleeding, pinpointing the kidney as the principal source of erythropoietin — the organ that would later be shown to house the oxygen sensor.
- Goldwasser purifies EPO (1977). Eugene Goldwasser at the University of Chicago, after decades of work, purified human EPO from roughly 2,550 liters of urine collected from aplastic-anemia patients, yielding a few milligrams of pure hormone. That protein sequence enabled the gene to be cloned in 1985 and recombinant epoetin alfa to reach patients in 1989.
- The HIF pathway (1990s–2019 Nobel). Gregg Semenza identified HIF-1 as the factor binding the EPO enhancer under hypoxia; Peter Ratcliffe and William Kaelin then showed that VHL and oxygen-dependent prolyl hydroxylation control HIF stability. Their combined work explained how cells sense oxygen and won the 2019 Nobel Prize in Physiology or Medicine — and directly produced the HIF prolyl-hydroxylase inhibitor drugs (e.g., roxadustat) now used to treat renal anemia by mimicking hypoxia.
Frequently asked questions
Where are red blood cells made and how fast?
In adults, red blood cells are made in the red bone marrow — chiefly the axial skeleton (vertebrae, sternum, ribs, pelvis) and the proximal ends of the femur and humerus. In the fetus, production shifts from the yolk sac to the liver and spleen, then to the marrow late in gestation. A healthy adult produces roughly 2 to 2.4 million erythrocytes every second, about 200 billion per day, to replace the same number that die after their roughly 120-day lifespan. That output can rise five- to tenfold under strong erythropoietin drive — for example after major blood loss or on ascent to high altitude — because expanded marrow and shortened maturation flood extra cells into the circulation. Erythrocytes account for about a quarter of all cells in the human body, so this steady replacement is one of the largest ongoing manufacturing jobs in physiology.
What does erythropoietin do and where is it made?
Erythropoietin (EPO) is a 30.4-kDa glycoprotein hormone that tells the bone marrow to make more red cells. In adults, roughly 90 percent of EPO is produced by peritubular interstitial fibroblasts in the renal cortex; the liver makes the rest and is the main source in the fetus. EPO binds the erythropoietin receptor (EPOR) on erythroid progenitors — mainly the colony-forming unit-erythroid (CFU-E) stage — and triggers JAK2 to phosphorylate STAT5. That signal blocks apoptosis and pushes progenitors to survive and mature into red cells. Without EPO, most CFU-E die by programmed cell death; with it, they survive. Because the kidney both senses oxygen and secretes EPO, chronic kidney disease causes anemia, and recombinant EPO (epoetin) is a standard treatment for it.
How does the kidney sense low oxygen through the HIF pathway?
The kidney senses oxygen through the hypoxia-inducible factor (HIF) pathway, the discovery that won Gregg Semenza, Peter Ratcliffe, and William Kaelin the 2019 Nobel Prize in Physiology or Medicine. HIF is a transcription factor with an oxygen-labile alpha subunit — HIF-2alpha is the one that drives EPO. When oxygen is plentiful, enzymes called prolyl hydroxylases (PHD1, PHD2, PHD3) use O2 as a substrate to hydroxylate two proline residues on HIF-2alpha. The von Hippel-Lindau (VHL) protein then recognizes the hydroxylated alpha subunit and marks it for destruction by the proteasome. When oxygen falls, the hydroxylases stall for lack of substrate, HIF-2alpha escapes degradation, pairs with HIF-1beta, and switches on the EPO gene. Because the sensor is the oxygen-dependent hydroxylase, EPO output rises steeply and almost immediately when tissue oxygen drops.
Why do red blood cells lose their nucleus?
During maturation, the orthochromatic erythroblast extrudes its condensed nucleus, ejecting it inside a thin rim of membrane; nearby marrow macrophages engulf the discarded nucleus. What remains is a reticulocyte that still carries ribosomes and residual RNA, which it uses to finish making hemoglobin over the next day or two before becoming a fully mature erythrocyte. Losing the nucleus (and later the mitochondria and other organelles) frees interior volume for hemoglobin — a mature human red cell is roughly one-third hemoglobin by weight, about 270 million molecules per cell — and lets the biconcave disc deform to squeeze through capillaries narrower than its own diameter. The cost is that the cell can no longer synthesize new proteins or repair itself, which is why it wears out and is culled after about 120 days. Mammals are unusual in enucleating; birds, fish, reptiles, and amphibians keep nucleated red cells.
Why does erythropoiesis need iron, vitamin B12, and folate?
Iron sits at the center of every heme group, and heme is what binds oxygen; about 70 percent of the body's 3 to 4 grams of iron is locked in hemoglobin, and the marrow consumes roughly 20 to 25 mg of iron per day, most of it recycled by macrophages from old red cells. Iron shortage produces small, pale (microcytic, hypochromic) cells because there is not enough hemoglobin to fill them. Vitamin B12 (cobalamin) and folate are both required to make the nucleotide thymidine for DNA synthesis; without them, erythroblasts cannot replicate their DNA on schedule even though the cytoplasm keeps growing, so cells enlarge and stall — the megaloblastic, macrocytic anemia of B12 or folate deficiency. In short, iron limits how much hemoglobin each cell can carry, while B12 and folate limit how fast the precursor cells can divide. All three must be adequate for normal red cell production.
How does altitude increase red blood cell count?
At altitude the air is thinner, so each breath delivers less oxygen and arterial oxygen saturation falls. The kidney's HIF pathway registers the drop and raises EPO — serum EPO can climb severalfold within a day or two of arriving at 4,000 meters. Higher EPO expands erythropoiesis, and over the following weeks hematocrit and total red cell mass rise, improving oxygen-carrying capacity. This is why endurance athletes train high or sleep in hypoxic tents (the live-high, train-low strategy). The adaptation has limits and downsides: excessive red cell production thickens the blood, and in some long-term high-altitude residents it becomes chronic mountain sickness (Monge's disease), with hematocrit above roughly 60 percent, headaches, and cardiovascular strain. Andean, Tibetan, and Ethiopian highland populations have each evolved distinct genetic adaptations — Tibetans, for instance, carry EPAS1 (HIF-2alpha) variants that keep hemoglobin lower and avoid the overshoot.
How does EPO doping work and why is it dangerous?
Blood doping raises the number of oxygen-carrying red cells to boost endurance. Athletes have done this by transfusing their own stored blood or, since the late 1980s, by injecting recombinant human erythropoietin (rhEPO) to drive their own marrow to make more red cells; more recently, HIF prolyl-hydroxylase inhibitors and EPO-mimetic peptides have appeared. The physiological gain is real — more red cells means more oxygen delivered to muscle — but the danger is that thicker, more viscous blood raises the risk of clots, stroke, heart attack, and, during exercise-driven dehydration, sudden cardiac death; a cluster of unexplained deaths among European cyclists in the late 1980s and 1990s is widely attributed to early EPO abuse. EPO has been banned in sport since the early 1990s. Because recombinant EPO is glycosylated slightly differently from the natural hormone, anti-doping labs can detect it by isoelectric focusing, and the Athlete Biological Passport flags the abnormal swings in reticulocyte count and hemoglobin that doping produces.